Discounted Cash Flow (DCF) Analysis Unlevered
Taysha Gene Therapies, Inc. (TSHA)
$0.688
+0.01 (+1.18%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|
| Revenue (%) | |||||||
| EBITDA | - | - | - | - | - | - | - |
| EBITDA (%) | |||||||
| EBIT | - | - | - | - | - | - | - |
| EBIT (%) | |||||||
| Depreciation | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Total Cash | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|
| Total Cash (%) | |||||||
| Account Receivables | - | - | - | - | - | - | - |
| Account Receivables (%) | |||||||
| Inventories | - | - | - | - | - | - | - |
| Inventories (%) | |||||||
| Accounts Payable | - | - | - | - | - | - | - |
| Accounts Payable (%) | |||||||
| Capital Expenditure | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.688 |
|---|---|
| Beta | 1.222 |
| Diluted Shares Outstanding | 17.67 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 9.262 |
| Total Debt | - |
| Total Equity | 12.15 |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash
Year A/P | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Tax Rate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIAT | - | - | - | - | - | - | - |
| Depreciation | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - |
| Capital Expenditure | -9.08 | -15.30 | - | - | - | - | - |
| UFCF | - | - | - | - | - | - | - |
| WACC | |||||||
| PV UFCF | - | - | - | - | - | - | - |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -149.10 |
| Equity Value | - |
| Shares Outstanding | 17.67 |
| Equity Value Per Share | - |